Eisai Co., Ltd. and Biogen Inc. jointly announced today that the Ministry of Food and Drug Safety in South Korea has given approval for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI"

Be Biopharma, Inc. has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for BE-101, a novel treatment for hemophilia B. This milestone marks a significant step forward in the company's efforts to develop Engineered B Cell Medicines

RevolKa Ltd., a venture-backed biotech company led by Norio Hamamatsu as President and CEO, has forged a significant partnership with Daiichi Sankyo Co., Ltd., under the leadership of President and COO Hiroyuki Okuzawa.

NS Pharma, Inc., a subsidiary of Nippon Shinyaku Co., Ltd., has released preliminary findings from its global Phase 3 clinical trial of NS-065/NCNP-01, commonly known as viltolarsen.

Eupraxia Pharmaceuticals Inc., has received approval from regulators in Australia and Canada to broaden its Phase 1b/2a RESOLVE trial, focusing on EP-104GI as a potential remedy for eosinophilic esophagitis

Coya Therapeutics, Inc., a biotechnology company in the clinical stage, recently completed a Phase 2 study of LD IL-2 in patients with mild-to-moderate Alzheimer's disease. Led by Drs. Stanley Appel and Alireza Faridar at Houston Methodist Hospital, the study

Antion Biosciences, based in Geneva, is at the forefront of cell and gene therapy with its latest breakthrough. They're pioneering the development of next-generation anti-CD19 chimeric antigen receptor

YGION Biomedical GmbH, a company specializing in personalized neoantigen-based cancer vaccines, has successfully completed a Series A financing round, securing €15 million from an Austrian private trust

Imvax, Inc., a biotechnology company specializing in personalized immunotherapies derived from whole tumors, has successfully enrolled participants in its Phase 2b clinical trial for IGV-001, designed for patients

Atara Biotherapeutics, Inc., a leading player in T-cell immunotherapy, has achieved a significant milestone by submitting a Biologics License Application to the U.S. Food and Drug Administration